Clinical trials: TACE
Hepatocellular Carcinoma
HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) in patients with BCLC stage hepatocellular carcinoma (HCC).
- Trial name
- NCT02856126
- Testing
- Hepatic arterial infusion chemotherapy, Transarterial chemoembolization, TACE regimen
- Where
- 7 sites in China
- Volunteers
- 214 people
- Sponsor
- Sun Yat-sen University
Hepatic Cell Carcinoma
Effectiveness of Drug Eluting TACE in Primary HCC
the aim of this work to compare effectiveness of drug-eluting bead trans-arterial chemo-embolization and conventional trans-arterial chemo-embolization of hepatic cell carcinoma in the aspect of (Tumor response via m-RECIST…
- Trial name
- NCT04048317
- Testing
- HepaSphere Microspheres/Doxorubicin Hydrochloride, Lipiodol
- Volunteers
- 75 people
- Sponsor
- Assiut University
Hepatocellular Carcinoma, Transarterial Chemoembolization
Survival According to the Feeding Artery Obliteration by Chemoembolization for Unresectable Hepatocellular Carcinoma
The aim of this study was to evaluate whether survival of patients who underwent TACE with unresectable HCC can benefit from intermediate-levels of embolization.
- Trial name
- NCT01677468
- Testing
- Intermediate embolization, Complete embolization
- Where
- 3 sites in South Korea
- Volunteers
- 250 people
- Sponsor
- Hallym University Medical Center
Liver Neoplasms
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
This phase II trial evaluates the diagnostic performance of contrast-enhanced ultrasound (CEUS) for assessing treatment response in patients undergoing transarterial chemoembolization (TACE) for liver tumors.
- Trial name
- NCT06261814
- Testing
- Sulfur Hexafluoride Lipid Microspheres, Contrast-Enhanced Ultrasound, Transarterial Chemoembolization
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- john eisenbrey
Hepatocellular Carcinoma
Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation
The purpose of this study is to evaluate the safety and efficacy of the combination of donafenib and TACE in the perioperative period of liver transplantation.
- Trial name
- NCT05576909
- Testing
- Donafenib, TACE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
HCC, Liver Cirrhosis
TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
In China, the majority of hepatocellular carcinoma (HCC) cases stem from chronic hepatitis B virus (HBV) infection and subsequent cirrhosis, with patients often presenting at the decompensated stage complicated by clinically…
- Conditions
- HCC, Liver Cirrhosis, Portal Hypertension
- Trial name
- NCT07350070
- Testing
- TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol
- Where
- 7 sites in China
- Volunteers
- 78 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma Non-resectable
The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma
To investigate the safety and efficacy of deferoxamine (DFO) combined with conventional transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT03652467
- Testing
- Conventional TACE, Deferoxamine and conventional TACE
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jinan Military General Hospital
Hepatocellular Carcinoma
Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
Transcatheter arterial chemoembolization (TACE) had been proved to improve the survivals for middle stage hepatocellular carcinoma (HCC), but for advanced stage HCC its' efficacy had not been proved.
- Trial name
- TACEHCC (NCT00646100)
- Testing
- transcatheter arterial chemoembolization
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Sun Yat-sen University
Cancer of Liver
Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation (RFA) Associated With Postoperative TACE
A RCT was conducted to elucidate whether the treatment outcome of HCC could be improved by RFA associated with postoperative TACE.
- Trial name
- NCT00730860
- Testing
- radiofrequency ablation associated with TACE, radiofrequency ablation only
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Southwest Hospital, China
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
This phase II trial studies the effect of transarterial chemoembolization in treating patients with uveal melanoma that has spread to the liver (liver metastases).
- Conditions
- Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Choroidal and Ciliary Body Melanoma AJCC V8
- Trial name
- NCT04728633
- Testing
- Carmustine, Ethiodized Oil, Transarterial Chemoembolization
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Thomas Jefferson University
Hepatocellular Carcinoma
Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC) is a primary liver cancer. It is the 6th most common malignancy and the 3rd killers of all tumors worldwide with an incidence of 626,000 new patients a year.
- Trial name
- NCT02729506
- Testing
- Transarterial Radioembolization, Transarterial Chemoembolization using drug-eluting beads
- Where
- Saudi Arabia
- Volunteers
- 150 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Hepatocellular Carcinoma (HCC)
TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC
This study is a single-arm, multicenter, prospective clinical trial designed to evaluate the efficacy and safety of Transarterial Chemoembolization (TACE) combined with envafolimab in patients with unresectable, non-metastatic…
- Trial name
- TACE HCC (NCT06990620)
- Testing
- TACE+AK112
- Volunteers
- 56 people
- Sponsor
- Fudan University
Unresectable Hepatocellular Carcinoma
DEB-TACE+HAIC vs. HAIC for Large HCC
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) plus hepatic artery infusion chemotherapy (HAIC) compared with HAIC alone for unresectable large…
- Trial name
- NCT05263219
- Testing
- dTACE-HAIC, HAIC, dTACE-HAIC protocol
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
Predictive Model for Pain After TACE
The main aim of this study was to analyze the risk factors that helped to predict the pain after transarterial chemoembolization (TACE).This was a prospective observational study enrolled all hepatocellular carcinoma (HCC)…
- Trial name
- NCT05545046
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Yantai Yuhuangding Hospital
Hepatocellular Carcinoma, Portal Vein Occlusion
TACE Combined With Iodine-125 Seeds Implantation for HCC
Portal vein tumour thrombus (PVTT) is a common complication of hepatocellular carcinoma (HCC). PVTT has a profound adverse effect on prognosis, with a very short median survival time (2-4 months).
- Conditions
- Hepatocellular Carcinoma, Portal Vein Occlusion, Tumor Thrombus
- Trial name
- NCT03322280
- Testing
- TACE combined with iodine-125 seeds implantation, TACE
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.
- Trial name
- BRISK TA (NCT00908752)
- Testing
- Brivanib, TACE Therapy
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 734 people
- Sponsor
- Bristol-Myers Squibb
HCC
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
This study will evaluate the efficacy and safety of TACE combined with atezolizumab + bevacizumab in the treatment of unresectable hepatocellular carcinoma, and the treatment patterns of the combination regimen
- Trial name
- CHANCE023 (NCT06024252)
- Testing
- TACE
- Volunteers
- 200 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
The purpose of the study is to observe the effect of Lenvatinib Combined With TACE in preventing the recurrence in high-risk patients with hepatocellular carcinoma.
- Trial name
- NCT03838796
- Testing
- lenvatinib, TACE
- Where
- China
- Volunteers
- 297 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
- Trial name
- NCT03642561
- Testing
- radiotherapy ablation, transarterial chemoembolization(TACE)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Nausea, Vomiting
Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE
Observation on acupoint electric stimulation combined with tropisetron in preventing and treating nausea and vomiting and improving the patient's appetite after TACE for primary or metastatic liver cancer patients.
- Conditions
- Nausea, Vomiting, Metastatic Liver Cancer
- Trial name
- NCT01895010
- Testing
- acupoint electric stimulation, tropisetron
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Fudan University